New combo therapy targets tough pancreatic cancer
NCT ID NCT03417921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ABTL0812 added to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has spread. The goal is to see if the combination is safe and works better than chemo alone. The trial was suspended, so results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ADENOCARCINOMA OF THE PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Marc Cortal
Barcelona, 08190, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?